HIT-LOGGIC

Low-grade gliomas of childhood and adolescence (LGG) are the most common brain tumors in these age groups and account for approximately 40-50 % of patients in Germany. The median age at diagnosis is between 6-8 years. About 7 % of all patients are diagnosed as infants.
The main purpose of the registry is to collect key characteristics of patients with LGG in Germany, regardless of whether they are included in a clinical trial. The objectives of this registry are manifold:

• Prospective demographic recording of primary, recurrent and chronic-progressive patients with an LGG
• Quality assurance by ensuring standardized central referencing of all essential diagnostic steps for all patients, especially if not primarily treated in a clinical trial
• Ensuring centralized counseling of patients and practitioners
• Collecting data on the therapies used in the course of treatment for comparison with the treatment results from the preliminary studies and registers
• Enabling the joint evaluation of the clinical data of patients from the precursor studies and registries with regard to long-term courses
• Long-term observation of patients who develop LGG in childhood and adolescence
• Recording of disease- and therapy-associated late effects
• Creation of a database of clinical data and, in cooperation with the LOGGIC core study, molecular data in order to be able to compare current and future studies (multi-state model)
• Provision of clinical information in order to be able to retrospectively evaluate subgroups
• Provision of centralized clinical data from patients with low-grade glioma registered in Germany for current and future national and international collaborations, such as the German Childhood Cancer Registry, the HIT-Life Consortium, the European SIOPE-BTG for Low-Grade Glioma (LOGGIC), the American COG and other partners
• Provision of central clinical and, in cooperation with the LOGGIC Core Study, biological data in order to be able to refer patients to future Phase I/II/III studies

Therapeutic interventions are not planned and will be carried out as needed through clinical trial protocols and/or according to the treatment recommendations of the European Working Group on Low-Grade Gliomas in Children and Adolescents.

• Diagnosis or suspicion of LGG by examination of tumor material or neuroradiological diagnosis confirmed by the reference center for neuroradiology
• From birth to 21 years of age
• Signed informed consent forms depending on the age and cognitive development of the patient and/or legal guardian